Histagas Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related mucosal damage and promoting ulcer healing. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control. Histagas Capsule SR is indicated for patients requiring both prokinetic and acid-suppressive therapy, particularly in cases where delayed gastric emptying and excessive acid secretion coexist. It is contraindicated in individuals with known hypersensitivity to either component, and caution is advised in patients with hepatic impairment or underlying cardiac conditions due to potential domperidone-related QT prolongation. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Clinical monitoring is recommended to optimize therapeutic outcomes and minimize risks.